Biotransformation of berberine

Biotransformation of berberine refers to the complex series of metabolic reactions that convert the isoquinoline alkaloid berberine into its various metabolites, a process that is critical for determining the compound's bioavailability and clinical efficacy. Despite its potent activity in treating metabolic disorders, berberine exhibits extremely low oral bioavailability (typically <1%), making its transformation by the gut microbiota and liver enzymes a primary focus of pharmacokinetic research. In the gastrointestinal tract, bacteria with nitroreductase activity reduce berberine into the more readily absorbable dihydroberberine, which is subsequently re-oxidized back to berberine upon entering the systemic circulation. Hepatic metabolism further processes the alkaloid through cytochrome P450 isoforms, specifically CYP2D6, CYP1A2, and CYP3A4, producing bioactive metabolites such as thalifendine, berberrubine, and demethyleneberberine. These metabolic products contribute to the drug's multi-target therapeutic profile, which includes the activation of AMP-activated protein kinase (AMPK) and the up-regulation of low-density lipoprotein receptors (LDLR). Understanding these biotransformation pathways is essential for optimizing berberine-based therapies for conditions such as type 2 diabetes, hyperlipidemia, and non-alcoholic fatty liver disease.

Other names

Berberine metabolismBBR biotransformationPhase I metabolism of berberineHepatic and intestinal metabolism of berberineMicrobial transformation of berberine

Biotransformation serves as a pharmacokinetic gateway where gut microbiota and hepatic enzymes convert the low-bioavailability parent compound berberine into more absorbable forms (e.g., dihydroberberine) and bioactive metabolites (e.g., thalifendine), which subsequently mediate systemic therapeutic effects.